Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RGLS 
Regulus Therapeutics Inc (RGLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/24/2025: RGLS (4-star) is a STRONG-BUY. BUY since 70 days. Profits (451.35%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 363.37% | Avg. Invested days 39 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 564.95M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 6 | Beta 0.37 | 52 Weeks Range 0.83 - 8.35 | Updated Date 07/1/2025 |
52 Weeks Range 0.83 - 8.35 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.23% | Return on Equity (TTM) -53.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 500988166 | Price to Sales(TTM) 7.43 |
Enterprise Value 500988166 | Price to Sales(TTM) 7.43 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 69234096 | Shares Floating 57670611 |
Shares Outstanding 69234096 | Shares Floating 57670611 | ||
Percent Insiders 2.71 | Percent Institutions 82.87 |
Analyst Ratings
Rating 2 | Target Price 7 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Regulus Therapeutics Inc
Company Overview
History and Background
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNA therapeutics, founded in 2007. It has focused on oligonucleotide therapies targeting microRNAs for various diseases.
Core Business Areas
- MicroRNA Therapeutics Development: Focuses on developing oligonucleotide drugs that modulate microRNA activity. The company's approach involves designing drugs to either block or mimic the activity of specific microRNAs associated with disease.
Leadership and Structure
The leadership team includes a CEO and a board of directors. The organizational structure comprises research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- RGLS4326: An oligonucleotide designed to inhibit microRNA-10b in autosomal dominant polycystic kidney disease (ADPKD). Clinical trials are underway. Competitors include companies developing other therapies for ADPKD. No specific market share or revenue data is publicly available for this pre-commercial product.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Companies focus on developing novel therapeutics for unmet medical needs. Success depends on clinical trial outcomes, regulatory approvals, and commercialization strategies.
Positioning
Regulus Therapeutics Inc. is positioned within the microRNA therapeutics niche. Its competitive advantage lies in its expertise in microRNA biology and oligonucleotide drug development.
Total Addressable Market (TAM)
The TAM for ADPKD is estimated to be in the billions of dollars. Regulus' positioning relative to this TAM depends on the clinical success and regulatory approval of RGLS4326.
Upturn SWOT Analysis
Strengths
- Expertise in microRNA biology
- Proprietary oligonucleotide drug development platform
- Clinical-stage product candidate (RGLS4326)
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
Opportunities
- Potential for strategic partnerships
- Expansion of microRNA therapeutic pipeline
- Positive clinical trial data for RGLS4326
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- VRTX
- OCUL
- ALNY
Competitive Landscape
Regulus Therapeutics Inc. is smaller and less capitalized compared to larger pharmaceutical companies. Its competitive advantage lies in its microRNA expertise. Competitors may have more advanced pipelines or larger commercialization capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on funding rounds and milestone payments from collaborations. The company's value has fluctuated based on clinical trial progress.
Future Projections: Future growth depends on the successful development and commercialization of RGLS4326 and other pipeline candidates. Analyst projections are heavily influenced by clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing RGLS4326 through clinical trials and seeking strategic partnerships.
Summary
Regulus Therapeutics is a high-risk, high-reward biopharmaceutical company specializing in microRNA therapeutics. Its success heavily relies on the clinical trial outcomes of RGLS4326. The company needs to secure funding to continue its research and development efforts. Potential threats include clinical trial failures and competition from larger companies. Positive clinical results could drive significant shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regulus Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-10-04 | CEO & Director Mr. Joseph P. Hagan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.regulusrx.com |
Full time employees 34 | Website https://www.regulusrx.com | ||
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.